Relapse in patients on long-term fluoxetine treatment

Response to increased fluoxetine dose

M. Fava, S. M. Rappe, J. A. Pava, A. A. Nierenberg, Jonathan E. Alpert, J. F. Rosenbaum

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Background: Although several studies have examined the long-term efficacy of antidepressants, relatively little attention has been paid to the management of relapses or recurrences during continued antidepressant treatment. This study examined whether depressed patients who had recovered and then relapsed on fluoxetine 20 mg/day would benefit from an increase in fluoxetine dose. Method: Eighteen patients who relapsed on fluoxetine 20 mg/day during long-term treatment with fluoxetine as part of a placebo controlled study had their fluoxetine dose raised to 40 mg/day and were followed for at least 1 month (mean time = 4.7 months). Results: Twelve (67%) were full responders, 3 (17%) partial responders, and 3 (17%) dropped out because of side effects (e.g., insomnia and agitation). Of those patients who had either full or partial response (N = 15; 83%), 3 complete responders had a recurrence on 40 mg/day after a mean of 5.8 months and 1 partial responder had a recurrence 11 months later. Overall, 11 (61%) of 18 patients maintained their response during their follow-up while taking the higher dose of fluoxetine. Conclusion: An increase in dose of fluoxetine to 40 mg/day appears to be an effective strategy in the treatment of relapse among depressed patients who had initially responded to fluoxetine 20 mg/day.

Original languageEnglish (US)
Pages (from-to)52-55
Number of pages4
JournalJournal of Clinical Psychiatry
Volume56
Issue number2
StatePublished - 1995
Externally publishedYes

Fingerprint

Fluoxetine
Recurrence
Therapeutics
Antidepressive Agents
Sleep Initiation and Maintenance Disorders
Placebos

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Fava, M., Rappe, S. M., Pava, J. A., Nierenberg, A. A., Alpert, J. E., & Rosenbaum, J. F. (1995). Relapse in patients on long-term fluoxetine treatment: Response to increased fluoxetine dose. Journal of Clinical Psychiatry, 56(2), 52-55.

Relapse in patients on long-term fluoxetine treatment : Response to increased fluoxetine dose. / Fava, M.; Rappe, S. M.; Pava, J. A.; Nierenberg, A. A.; Alpert, Jonathan E.; Rosenbaum, J. F.

In: Journal of Clinical Psychiatry, Vol. 56, No. 2, 1995, p. 52-55.

Research output: Contribution to journalArticle

Fava, M, Rappe, SM, Pava, JA, Nierenberg, AA, Alpert, JE & Rosenbaum, JF 1995, 'Relapse in patients on long-term fluoxetine treatment: Response to increased fluoxetine dose', Journal of Clinical Psychiatry, vol. 56, no. 2, pp. 52-55.
Fava, M. ; Rappe, S. M. ; Pava, J. A. ; Nierenberg, A. A. ; Alpert, Jonathan E. ; Rosenbaum, J. F. / Relapse in patients on long-term fluoxetine treatment : Response to increased fluoxetine dose. In: Journal of Clinical Psychiatry. 1995 ; Vol. 56, No. 2. pp. 52-55.
@article{424992dbf0464b54b07cdc711336c49c,
title = "Relapse in patients on long-term fluoxetine treatment: Response to increased fluoxetine dose",
abstract = "Background: Although several studies have examined the long-term efficacy of antidepressants, relatively little attention has been paid to the management of relapses or recurrences during continued antidepressant treatment. This study examined whether depressed patients who had recovered and then relapsed on fluoxetine 20 mg/day would benefit from an increase in fluoxetine dose. Method: Eighteen patients who relapsed on fluoxetine 20 mg/day during long-term treatment with fluoxetine as part of a placebo controlled study had their fluoxetine dose raised to 40 mg/day and were followed for at least 1 month (mean time = 4.7 months). Results: Twelve (67{\%}) were full responders, 3 (17{\%}) partial responders, and 3 (17{\%}) dropped out because of side effects (e.g., insomnia and agitation). Of those patients who had either full or partial response (N = 15; 83{\%}), 3 complete responders had a recurrence on 40 mg/day after a mean of 5.8 months and 1 partial responder had a recurrence 11 months later. Overall, 11 (61{\%}) of 18 patients maintained their response during their follow-up while taking the higher dose of fluoxetine. Conclusion: An increase in dose of fluoxetine to 40 mg/day appears to be an effective strategy in the treatment of relapse among depressed patients who had initially responded to fluoxetine 20 mg/day.",
author = "M. Fava and Rappe, {S. M.} and Pava, {J. A.} and Nierenberg, {A. A.} and Alpert, {Jonathan E.} and Rosenbaum, {J. F.}",
year = "1995",
language = "English (US)",
volume = "56",
pages = "52--55",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "2",

}

TY - JOUR

T1 - Relapse in patients on long-term fluoxetine treatment

T2 - Response to increased fluoxetine dose

AU - Fava, M.

AU - Rappe, S. M.

AU - Pava, J. A.

AU - Nierenberg, A. A.

AU - Alpert, Jonathan E.

AU - Rosenbaum, J. F.

PY - 1995

Y1 - 1995

N2 - Background: Although several studies have examined the long-term efficacy of antidepressants, relatively little attention has been paid to the management of relapses or recurrences during continued antidepressant treatment. This study examined whether depressed patients who had recovered and then relapsed on fluoxetine 20 mg/day would benefit from an increase in fluoxetine dose. Method: Eighteen patients who relapsed on fluoxetine 20 mg/day during long-term treatment with fluoxetine as part of a placebo controlled study had their fluoxetine dose raised to 40 mg/day and were followed for at least 1 month (mean time = 4.7 months). Results: Twelve (67%) were full responders, 3 (17%) partial responders, and 3 (17%) dropped out because of side effects (e.g., insomnia and agitation). Of those patients who had either full or partial response (N = 15; 83%), 3 complete responders had a recurrence on 40 mg/day after a mean of 5.8 months and 1 partial responder had a recurrence 11 months later. Overall, 11 (61%) of 18 patients maintained their response during their follow-up while taking the higher dose of fluoxetine. Conclusion: An increase in dose of fluoxetine to 40 mg/day appears to be an effective strategy in the treatment of relapse among depressed patients who had initially responded to fluoxetine 20 mg/day.

AB - Background: Although several studies have examined the long-term efficacy of antidepressants, relatively little attention has been paid to the management of relapses or recurrences during continued antidepressant treatment. This study examined whether depressed patients who had recovered and then relapsed on fluoxetine 20 mg/day would benefit from an increase in fluoxetine dose. Method: Eighteen patients who relapsed on fluoxetine 20 mg/day during long-term treatment with fluoxetine as part of a placebo controlled study had their fluoxetine dose raised to 40 mg/day and were followed for at least 1 month (mean time = 4.7 months). Results: Twelve (67%) were full responders, 3 (17%) partial responders, and 3 (17%) dropped out because of side effects (e.g., insomnia and agitation). Of those patients who had either full or partial response (N = 15; 83%), 3 complete responders had a recurrence on 40 mg/day after a mean of 5.8 months and 1 partial responder had a recurrence 11 months later. Overall, 11 (61%) of 18 patients maintained their response during their follow-up while taking the higher dose of fluoxetine. Conclusion: An increase in dose of fluoxetine to 40 mg/day appears to be an effective strategy in the treatment of relapse among depressed patients who had initially responded to fluoxetine 20 mg/day.

UR - http://www.scopus.com/inward/record.url?scp=0028902777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028902777&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 52

EP - 55

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 2

ER -